These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35192139)

  • 1. Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.
    Pugh-Toole M; Nicolela AP; Nersesian S; Leung BM; Boudreau JE
    Curr Treat Options Oncol; 2022 Feb; 23(2):210-226. PubMed ID: 35192139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.
    Gonzalez VD; Huang YW; Delgado-Gonzalez A; Chen SY; Donoso K; Sachs K; Gentles AJ; Allard GM; Kolahi KS; Howitt BE; Porpiglia E; Fantl WJ
    Cell Rep; 2021 Aug; 36(9):109632. PubMed ID: 34469729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
    Nersesian S; Arseneau RJ; Mejia JP; Lee SN; Westhaver LP; Griffiths NW; Grantham SR; Meunier L; Communal L; Mukherjee A; Mes-Masson AM; Arnason T; Nelson BH; Boudreau JE
    Front Immunol; 2023; 14():1307873. PubMed ID: 38318505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
    Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
    Front Immunol; 2019; 10():1782. PubMed ID: 31456796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer treatment and natural killer cell-based immunotherapy.
    Fan Z; Han D; Fan X; Zhao L
    Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Gelsolin Inhibits Natural Killer Cell Function and Confers Chemoresistance in Epithelial Ovarian Cancer.
    Onuma T; Asare-Werehene M; Fujita Y; Yoshida Y; Tsang BK
    Cells; 2024 May; 13(11):. PubMed ID: 38891037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem-cell based, machine learning approach for optimizing natural killer cell-based personalized immunotherapy for high-grade ovarian cancer.
    Esmail S; Danter WR
    FEBS J; 2022 Feb; 289(4):985-998. PubMed ID: 34582617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
    Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.
    Henriksen JR; Donskov F; Waldstrøm M; Jakobsen A; Hjortkjaer M; Petersen CB; Dahl Steffensen K
    Acta Oncol; 2020 Jun; 59(6):652-659. PubMed ID: 31931651
    [No Abstract]   [Full Text] [Related]  

  • 16. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
    Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
    Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
    Truxova I; Kasikova L; Hensler M; Skapa P; Laco J; Pecen L; Belicova L; Praznovec I; Halaska MJ; Brtnicky T; Salkova E; Rob L; Kodet R; Goc J; Sautes-Fridman C; Fridman WH; Ryska A; Galluzzi L; Spisek R; Fucikova J
    J Immunother Cancer; 2018 Dec; 6(1):139. PubMed ID: 30526667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 19. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer.
    Elanany MM; Mostafa D; Hamdy NM
    Life Sci; 2023 Oct; 330():121997. PubMed ID: 37536617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.